<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889564</url>
  </required_header>
  <id_info>
    <org_study_id>11-0050</org_study_id>
    <nct_id>NCT00889564</nct_id>
  </id_info>
  <brief_title>HeRO Vascular Access Device Bacteremia Study</brief_title>
  <official_title>HeRO Vascular Access Device Bacteremia Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integra Clinical Trial Solutions - statistical analysis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ross, John, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merit Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of the HeRO Vascular&#xD;
      Access Device in access challenged (e.g., catheter-dependent) hemodialysis patients. It is&#xD;
      hypothesized the bacteremia rate associated with the HeRO device will be lower than a&#xD;
      historical literature control of tunneled dialysis catheters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HeRO superiority in device and implant procedure-related bacteremia compared to historical tunneled dialysis catheter literature control</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious device or implant procedure-related serious adverse events and loss of secondary patency</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Hemodialysis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeRO Vascular Access Device</intervention_name>
    <description>Long-term subcutaneous vascular access device for hemodialysis</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 21 years of age or older.&#xD;
&#xD;
          2. Male or non-pregnant female.&#xD;
&#xD;
          3. Life expectancy less than 1 year.&#xD;
&#xD;
          4. ESRD on hemodialysis with poor remaining venous access sites for creation of an AV&#xD;
             fistula or placement of a graft in the upper extremities.&#xD;
&#xD;
          5. Implant side central venous system that surgeon believes can be accessed with&#xD;
             interventional devices and can accommodate the 19 Fr GVAS device.&#xD;
&#xD;
          6. Potential GVAS target brachial artery â‰¥ 3 mm in diameter determined by any suitable&#xD;
             measure.&#xD;
&#xD;
          7. Ability to understand and provide written informed consent.&#xD;
&#xD;
          8. Willing and able to cooperate with follow-up examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented history of drug abuse within six months prior to enrollment.&#xD;
&#xD;
          2. &quot;Planned&quot; concomitant surgical procedure or previous major surgery within 30 days,&#xD;
             excluding vascular access related procedures.&#xD;
&#xD;
          3. Currently being treated with another investigational device or drug.&#xD;
&#xD;
          4. Known bleeding diathesis or hypercoaguable state.&#xD;
&#xD;
          5. Peripheral white blood cell count 1.5 K/mm3 or platelet count 50 K/mm3.&#xD;
&#xD;
          6. Degenerative connective tissue disease, e.g., Marfan's and Ehlers Danlos Syndrome.&#xD;
             Subjects with Lupus Erythematosus may be enrolled if receiving no immunosuppressants&#xD;
             or low dose prednisone only (&lt; 10 mg/day orally).&#xD;
&#xD;
          7. Subjects with known or suspected concomitant active bacterial, fungal, viral, or&#xD;
             parasitic infection. Subjects with Hepatitis B and/or Hepatitis C may be enrolled.&#xD;
             Subjects who are HIV + with CD4 count of &lt; 200 are excluded. Subjects with bacteremia&#xD;
             within the past six (6) weeks must have negative blood cultures one week after&#xD;
             completing appropriate antibiotic therapy prior to enrollment.&#xD;
&#xD;
          8. Severe underlying co-morbidity or immediate life-threatening condition.&#xD;
&#xD;
          9. Subjects with any condition which, in the opinion of the investigator, could preclude&#xD;
             evaluation of response or completion of follow-up or affect subject safety.&#xD;
&#xD;
         10. Subjects with significant arterial occlusive disease which would preclude safe&#xD;
             placement of an upper extremity hemodialysis access.&#xD;
&#xD;
         11. Subjects with history or findings on physical examination suggesting significant&#xD;
             arterial insufficiency that could affect patient safety and/or device performance in&#xD;
             the extremity planned for use with GVAS (i.e., steal syndrome, hand ischemia,&#xD;
             peripheral arterial vascular disease, etc.).&#xD;
&#xD;
         12. Subjects with scheduled kidney transplant within the next 12 months.&#xD;
&#xD;
         13. Subjects with history of superior vena cava syndrome are excluded unless it was&#xD;
             induced by previous access (these subjects can be enrolled).&#xD;
&#xD;
         14. Subjects with history of decreased cardiac output with ejection fraction &lt; 20% and/or&#xD;
             NYHA class III or IV. NYHA definitions: Class III - Subjects with marked limitation of&#xD;
             activity; they are comfortable only at rest; Class IV - Subjects who should be at&#xD;
             complete rest, confined to bed or chair; any physical activity brings on discomfort&#xD;
             and symptoms occur at rest.&#xD;
&#xD;
         15. Subjects with history of uncorrected hypotension with systolic blood pressures&#xD;
             routinely &lt; 100 mg Hg.&#xD;
&#xD;
         16. Subjects who currently have a pacemaker or ICD in their central venous system on the&#xD;
             same side where the GVAS device would be implanted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bamberg County Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami / Cedars Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamberg County Hospital</name>
      <address>
        <city>Bamberg</city>
        <state>South Carolina</state>
        <zip>29003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Heart Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular access for hemodialysis</keyword>
  <keyword>Catheter dependent patients</keyword>
  <keyword>Access challenged patients</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>HeRO Vascular Access Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

